Email
TextLatest News on Clinical Trials
Can-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South Korea; Results of its NASH Phase II Study are Expected this Quarter
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today it has been granted patent...
Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis
TORONTO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel cannabinoid-based and life sciences products, is pleased to provide an update on the...
Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology
Pivotal Phase 3 trial of zilucoplan in gMG ongoing, with top-line results expected in early 2021 February 18, 2020 07:00 AM Eastern Standard Time CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that full results from its Phase...
Phase 3 Trial to Assess Dapivirine Ring for Safety in Pregnant Women
Various alternatives to a daily pill for HIV pre-exposure prophylaxis (PrEP) have are being evaluated to ease the burden on patients and increase adherence to the regimen. The National Institutes of Health (NIH) has launched the first clinical trial evaluating the...
WPD Pharmaceuticals’ WP1220 Drug Demonstrates Median Reduction of 56% in Skin Cancer Lesions in Clinical Trials
Data Presented at the 4th Annual World Congress of Cutaneous Lymphomas in Barcelona, Feb 2020 VANCOUVER, British Columbia, Feb. 18, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical...
Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106
NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid...
Investigational Subcutaneous Formulation of Vedolizumab Achieves Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn’s Disease
New data from the VISIBLE 2 trial presented at the 15th Congress of the European Crohn’s and Colitis Organisation (ECCO) Osaka, JAPAN, February 14, 2020 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from the phase 3...
ReNeuron Group plc – Positive Phase 2a stroke clinical data published
Positive Phase 2a stroke clinical data published ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce the publication in a peer reviewed journal of positive clinical data from the PISCES II Phase 2a...
New plant-based cancer drug shows treatment potential in Phase I trial
There may be hope for an effective plant-based treatment for various head and neck cancers, according to a new study conducted by researchers at UCLA. The organization posted an update to its findings in the last week, which aims to treat the 650,000 cases that are...
Veritas Pharma Announces Preliminary Clinical Trial Results and the Company’s New Direction
(MENAFN - Newsfile Corp) Veritas Pharma Announces Preliminary Clinical Trial Results and the Company's New Direction Vancouver, British Columbia--(Newsfile Corp. - February 13, 2020) - Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FSE: 2VP) ("Veritas" or the "Company")...
SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)
JERSEY CITY, N.J., Feb. 13, 2020 /PRNewswire/ --SCYNEXIS, Inc., Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that it has completed patient enrollment in its...
CytoDyn Reports Continued Positive Clinical Data on its Phase 1b/2 mTNBC and Expanded Access Studies for MBC Ahead of Breakthrough Therapy Designation Decision From the FDA
Patient #1: Enrolled in mTNBC Phase 1b/2 - Injected on 9/27/2019. CTC (circulating tumor cells) dropped to zero in two weeks on 10/11/2019. Total CTC and EMT (Epithelial Mesenchymal Transition in Tumor Metastasis) dropped to zero after about one month of treatment...
Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b/2 Clinical Trial of Ciforadenant at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers Symposium
BURLINGAME, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection,...
New Phase 3b Interim Data from STARDUST Study Show Two-Thirds of Patients with Moderately to Severely Active Crohn’s Disease Achieved Clinical Remission After Two Doses of STELARA® (ustekinumab)
First Study to Explore a Treat-to-Target Strategy in Crohn’s Disease using Endoscopy to Guide Dose Adjustment First Study to Evaluate Intestinal Ultrasound Monitoring in an Interventional Setting VIENNA--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson...
Innovation Pharmaceuticals Phase 1 Trial of Brilacidin for Ulcerative Colitis Meets Primary Endpoints; Positive Topline Results of Oral Brilacidin
WAKEFIELD, Mass., Feb. 13, 2020 (GLOBE NEWSWIRE) --Innovation Pharma (Formerly known as Cellceutix) (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to announce that preliminary top-line data from its Phase 1 trial (NCT03234465)...
Atreca Announces First Patient Dosed in Phase 1b Clinical Trial of ATRC-101 in Patients with Select Solid Tumors
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response,...
Adamas To Present Analysis of Clinical Trials on GOCOVRI® Treatment at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress
EMERYVILLE, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, announced today two...
Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer’s Disease
BERWYN, Pa., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases, announced today that the Data Safety Monitoring Board has reviewed...
Biophytis – Protocol Amendment of SARA-INT, a Phase 2b Clinical Trial of Sarconeos (BIO101) in Sarcopenia, Cleared by FDA and AFMPS
Following this clearance, SARA-INT trial to recruit 231 patients vs. 334 initially planned More than 80% of patients are now recruited - completion of patient recruitment expected in Q2 2020 Interim analysis by the study’s data safety and monitoring board (DSMB)...
Cassava Sciences Announces Phase 2a Study of PTI-125 Published in The Journal of Prevention of Alzheimer’s Disease (JPAD)
AUSTIN, Texas, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that The Journal of Prevention of Alzheimer’s Disease (JPAD), a peer-reviewed journal for the...